Our Science
Our Approach
Innovating cancer care, by design
Immunotherapies have transformed cancer treatment, but considerable challenges remain. Many people living with cancer are not eligible for immunotherapies, and among those who are eligible, only a small portion respond well to current treatments. At Mural Oncology, we are working to increase the number of patients who can benefit from immunotherapy.
Innovative Protein Engineering
For cancer therapies
Through the application of our industry-leading protein engineering capabilities, we are working to develop first and best-in-class drugs that can benefit patients across a wide range of cancers, including difficult-to-treat tumor types where immunotherapies have not yet been effective.
Explore
Our Pipeline
We are developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available today.
Nemvaleukin Alfa - IL-2 Variant
| Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Discovery Programs
| Program | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
Understanding OUR
Cytokine-Based Immunotherapy Candidates
Our commitment extends to advancing a robust portfolio of programs aimed at expanding the horizons of cytokine-based immunotherapy, especially for cancers where treatment options remain limited. Use the links below to learn more about our portfolio of cytokine-based immunotherapy candidates.
Nemvaleukin alfa (Nemvaleukin) – Novel engineered IL-2
Nemvaleukin, an engineered IL-2 variant, maximizes anti-cancer potential and minimizes toxicity by activating CD8 T cells and NK cells, making it a promising candidate in cancer immunotherapy.
Tumor-Targeted Split IL-12
The split IL-12 program safely delivers IL-12's therapy by directing inactive components to the tumor site via tumor-specific antibodies, reducing systemic toxicities and promoting anti-cancer immune responses.
Enhanced Efficacy IL-18
Enhanced efficacy IL-18 is an innovative variant of IL-18 engineered to evade binding with IL-18BP, thus aiming to unleash the full therapeutic potential of the IL-18 pathway for cancer treatment.